Department of Radiology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
J Ultrasound Med. 2019 Jul;38(7):1733-1738. doi: 10.1002/jum.14861. Epub 2018 Nov 13.
To evaluate a new commercial image-processing technique (MicroPure; Toshiba America Medical Systems, Tustin, CA) for detection and characterization of breast microcalcifications in patients undergoing stereotactic or ultrasound-guided biopsies using mammography as the reference standard.
One hundred female patients, with a total of 104 lesions, scheduled for an image-guided biopsy of an area with breast microcalcifications (identified on a prior mammogram) underwent MicroPure examinations of the breast using an Aplio XG scanner (Toshiba America Medical Systems) with a broad-bandwidth linear array. MicroPure combines nonlinear imaging and speckle suppression to mark suspected calcifications as white spots in a blue overlay image. Four independent and blinded readers (2 radiologists and 2 physicists) analyzed 208 digital clips consisting of dual grayscale ultrasound and MicroPure imaging, counting the number of microcalcifications seen with MicroPure. The observers also assessed the level of suspicion on a qualitative, visual analog, 6-point scale from 0 (no findings) over 1 (benign) to 5 (malignant).
The mean number of microcalcifications ± SD seen was 6.3 ± 3.5, whereas mammography saw 28.9 ± 24.6 (P = .66). When the MicroPure level of suspicion scores were compared with pathologic results using a receiver operating characteristic curve analysis, the areas under the curve ranged from 0.54 to 0.59. Nonetheless, malignant cases were seen to have significantly more microcalcifications than benign cases (mean number of microcalcifications, 6.9 ± 5.1 versus 5.3 ± 3.7; P = .02).
MicroPure can be used to identify areas with breast microcalcifications but cannot effectively characterize such areas. Instead, MicroPure may represent a new imaging method for guiding a biopsy to areas of microcalcifications.
使用乳腺钼靶摄影作为参考标准,评估一种新的商业图像处理技术(MicroPure;东芝美国医疗系统公司,加利福尼亚州图森市)在接受立体定向或超声引导活检的患者中检测和描述乳腺微钙化的性能。
100 名女性患者,共 104 个病灶,计划对乳腺微钙化区域(在之前的乳腺 X 线摄影中发现)进行影像引导活检,使用东芝美国医疗系统公司的 Aplio XG 扫描仪(宽频带线阵探头)进行 MicroPure 检查。MicroPure 结合非线性成像和斑点抑制技术,将可疑钙化标记为蓝色叠加图像中的白点。4 名独立且盲法的观察者(2 名放射科医生和 2 名物理学家)分析了 208 个数字剪辑,包括双灰度超声和 MicroPure 成像,计算 MicroPure 可见的微钙化数量。观察者还使用 0(无发现)到 1(良性)到 5(恶性)的 6 分制定性视觉模拟量表评估可疑程度。
平均微钙化数量 ± 标准差为 6.3 ± 3.5,而乳腺 X 线摄影为 28.9 ± 24.6(P = .66)。当使用受试者工作特征曲线分析比较 MicroPure 可疑程度评分与病理结果时,曲线下面积范围为 0.54 至 0.59。尽管如此,恶性病例的微钙化数量明显多于良性病例(平均微钙化数量,6.9 ± 5.1 与 5.3 ± 3.7;P = .02)。
MicroPure 可用于识别乳腺微钙化区域,但无法有效描述此类区域。相反,MicroPure 可能代表一种新的成像方法,可用于引导对微钙化区域进行活检。